miRNA 221 improved left ventricular contractile function in MIRI mice. حسب Hongyu Li (1332669)

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. حسب Mohammad Bakhtiari (11838264)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. حسب Chen Lu (135200)

Effect of BM-MSCs in improving DCS induced lung injury. حسب Chen Lu (135200)

General procedure for the synthesis of A and A-c1. حسب Xueqin lu (22250795)

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

Participants enrollment. حسب Chikondi Maluwa (20660522)

"…Attitude improved from 16.76 (93.1%) at baseline to 17.74 (98.6%) at the six-week mark. …"

KAP assessment scores (n = 422). حسب Chikondi Maluwa (20660522)

"…Attitude improved from 16.76 (93.1%) at baseline to 17.74 (98.6%) at the six-week mark. …"

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). حسب Xueqin lu (22250795)

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... حسب Xueqin lu (22250795)

General procedure for the synthesis of Kylo-0603. حسب Xueqin lu (22250795)

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... حسب Xueqin lu (22250795)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

General procedure for the synthesis of B. حسب Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. حسب Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). حسب Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. حسب Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. حسب Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"